DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20173279

Comparative evaluation of cost-effectiveness between typical antipsychotic haloperidol and atypical antipsychotics olanzapine, risperidone and aripiprazole in the treatment of stable schizophrenia

Subhash Vishal, Mirza A. Beg, Shakti B. Dutta, Sumit Khatri, Shobhit Garg, Nand Kishore Singh, Amanjot Kaur

Abstract


Background: Schizophrenia patients mostly require life-long treatment. For such long-term treatments, cost is an important factor. Estimate of cost in terms of efficacy can give idea to prescribers about the relative financial burden posed by various typical and newer antipsychotics in schizophrenic patients.

Methods: A total of 98 stable schizophrenic patients were enrolled in this open label study over a period of 1 year. Patients were divided in four groups, group-I received Haloperidol (n=24), group-II received Olanzapine (n=25), group-III received Risperidone (n=25) and group-IV received Aripiprazole (n=24). The patients were given drugs on the basis of physician’s discretion, depending upon the condition of the patient at the time of presentation. Patients were followed up to 16 weeks. Direct treatment costs and efficacy of treatment in terms of Clinical Global Impression - Efficacy Index CGI (EI) noted and average cost-effectiveness worked out.

Results: In this open label study, the mean age of patients was 35.05±1.30. The average cost-effectiveness ratio was 26.25 for haloperidol, 10.12 for Olanzapine, 9.83 for Risperidone and 25.92 for Aripiprazole.

Conclusions: Risperidone was found to be most cost-effective, followed by olanzapine, then by aripiprazole, whereas haloperidol was found least cost effective.


Keywords


Atypical, Antipsychotics, Aripiprazole, Cost-effectiveness, Haloperidol, Olanzapine, Risperidone, Typical/atypical antipsychotics

Full Text:

PDF

References


Freedman R. Drug Therapy Schizophrenia. N Engl J Med. 2003;349(18):1738-49.

Reus VI. Mental Disorders. In: Kasper, Fauci, Hauser, Longo, Jameson, Loscalzo et al Harrison’s principles of internal medicine 19th Ed. McGraw-Hill Education. U.S.A.; 2015:2708-2721.

Sadock BJ, Sadock VA. Schizophrenia. In: Text Book of Kaplan & Sadock's Synopsis of Psychiatry Behavioral Sciences / Clinical Psychiatry. 10th Ed. Lippincott Williams and Wilkins. Philadelphia. U.S.A.; 2013:470.

Sadock BJ, Sadock VA. Dopamine Receptor Antagonists. In: Text Book of Kaplan and Sadock's Synopsis of Psychiatry Behavioral Sciences / Clinical Psychiatry 9th Ed. Lippincott Williams and Wilkins. Philadelphia. U.S.A.; 2003:1050.

Sadock BJ, Sadock VA. Dopamine Receptor Antagonists. Typical Antipsychotics. In: Kaplan and Sadock's Synopsis of Psychiatry Behavioral Sciences / Clinical Psychiatry 10th Ed. Lippincott Williams and Wilkins. Philadelphia. U.S.A.; 2013:1043-1044.

Aruna D, Sudhakar TP. A retrospective study of the functional outcome of schizophrenia depending on premorbid personality at the time of diagnosis. J Clin Sci Res. 2014;3:166-73.

Koujalgi SR, Patil SR. Comparison of demographic profile of patient with schizophrenia and depression. Journal of the Scientific Society. 2013;40(1):20-4.

Mandal P, Prakash S, Sagar R. Primary caregivers of schizophrenia outpatients: burden and its correlates. Delhi Psychiatry Journal. 2014;17(2):343-8.

Saravanan B, Jakob KS, Johnson S, Prince M, Bhugra D, David AS. Outcome of first-episode schizophrenia in India: longitudinal study of effect of insight and psychopathology. The British Journal of Psychiatry. 2010;196:454-9.

Edgell ET, Andersen SW, Johnstone BM, Dulisse B, Revicki D, Breier A. Olanzapine versus risperidone. A prospective comparison of clinical and economic outcomes in schizophrenia. Pharmacoeconomics. 2000 Dec;18(6):567-79.

Foster RH. A pharmacoeconomic review of its use in schizophrenia. Pharmacoeconomics. 1999;15:611-40.